A real-world cohort observational study to compare effectiveness of sotrovimab versus molnupiravir to prevent severe COVID-19 outcomes in non-hospitalised high-risk COVID-19 adult patients using using OpenSAFELY Platform
Latest Information Update: 28 Sep 2022
At a glance
- Drugs Molnupiravir (Primary) ; Sotrovimab (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
Most Recent Events
- 28 Sep 2022 New trial record
- 28 Aug 2022 Results presented at the 38th International Conference on Pharmacoepidemiology and Therapeutic Risk Management